GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » JCR Pharmaceuticals Co Ltd (TSE:4552) » Definitions » Price-to-Owner-Earnings

JCR Pharmaceuticals Co (TSE:4552) Price-to-Owner-Earnings : (As of Jun. 06, 2024)


View and export this data going back to 2011. Start your Free Trial

What is JCR Pharmaceuticals Co Price-to-Owner-Earnings?

As of today (2024-06-06), JCR Pharmaceuticals Co's share price is 円567.00. JCR Pharmaceuticals Co does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for JCR Pharmaceuticals Co's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of JCR Pharmaceuticals Co was 762.39. The lowest was 37.88. And the median was 62.30.


TSE:4552's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 25.47
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-06), JCR Pharmaceuticals Co's share price is 円567.00. JCR Pharmaceuticals Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was 円43.91. Therefore, JCR Pharmaceuticals Co's PE Ratio for today is 12.91.

As of today (2024-06-06), JCR Pharmaceuticals Co's share price is 円567.00. JCR Pharmaceuticals Co's EPS without NRI for the trailing twelve months (TTM) ended in was 円44.02. Therefore, JCR Pharmaceuticals Co's PE Ratio without NRI for today is 12.88.

During the past 13 years, JCR Pharmaceuticals Co's highest PE Ratio without NRI was 149.51. The lowest was 12.88. And the median was 54.61.


JCR Pharmaceuticals Co Price-to-Owner-Earnings Historical Data

The historical data trend for JCR Pharmaceuticals Co's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JCR Pharmaceuticals Co Price-to-Owner-Earnings Chart

JCR Pharmaceuticals Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

JCR Pharmaceuticals Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of JCR Pharmaceuticals Co's Price-to-Owner-Earnings

For the Drug Manufacturers - General subindustry, JCR Pharmaceuticals Co's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


JCR Pharmaceuticals Co's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, JCR Pharmaceuticals Co's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where JCR Pharmaceuticals Co's Price-to-Owner-Earnings falls into.



JCR Pharmaceuticals Co Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

JCR Pharmaceuticals Co's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=567.00/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


JCR Pharmaceuticals Co  (TSE:4552) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


JCR Pharmaceuticals Co Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of JCR Pharmaceuticals Co's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


JCR Pharmaceuticals Co (TSE:4552) Business Description

Traded in Other Exchanges
Address
3-19 Kasuga-cho, Ashiya, Hyogo, JPN, 659-0021
JCR Pharmaceuticals Co Ltd is a major drug manufacturing company proactively engaged in the research of enzymes and proteins. The company maintains a focus toward developing value-added treatment options to address unmet medical needs. JCR utilizes international partnerships as a component of its growth strategy. The vast majority of JCR's revenue is generated from its pharmaceutical operations, followed by medical devices and laboratory equipment. A portion of the company's sales are derived from licensing agreements.

JCR Pharmaceuticals Co (TSE:4552) Headlines

No Headlines